Keros Therapeutics Inc (KROS NASDAQ) stock market data APIs
$17.7299
-0.26(-1.5%)
as of February 6, 2026
Try our APIs with
free plan!
Keros Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Prev. Close
17.7299
Open
17.4681
High
17.7543
Low
17.2821
52 wk Range
9.12-22.55
Market Cap
525 M
P/E Ratio
11.5705
Shares Outstanding
30 466 K
Revenue
247 M
EPS
-0.18
Beta
0.844
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Keros Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Keros Therapeutics Inc data using free add-ons & libraries
Get Keros Therapeutics Inc Fundamental Data
Keros Therapeutics Inc Fundamental data includes:
- Net Revenue: 247 M
- EBITDA: 47 926 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -1.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Keros Therapeutics Inc News
New
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Bristol Myers’ BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) ag...
Is KROS' KER-065 the Next Breakthrough in DMD Space?
Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming ...
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Clinical-stage biopharma company Janux Therapeutics JANX announced a strategic collaboration and exclusive global license agreement with biotech giant Bristol Myers Squibb BMY. The partnership center...
Get Keros Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
